BD to Highlight Advanced Biologics and Large-Volume Delivery Solutions at Pharmapack 2026

FRANKLIN LAKES, N.J. (January 19, 2026) - BD (Becton, Dickinson and Company), a leading global medical technology company, will present its latest drug delivery innovations at Pharmapack 2026, Europe's leading drug delivery event, taking place January 21-22, 2026, at Paris Expo.

Focus at Pharmapack

BD will demonstrate how its portfolio supports the evolving needs of pharmaceutical and biotechnology companies developing biologics -GLP-1 therapies, vaccines, and acute care medicines - as the industry advances patient self-administration and home-based care models. Additionally, BD will share how its broad range of ZebraSci services can help de-risk combination product development.

"As patient expectations continue to evolve and biologics become more complex, drug delivery systems must balance performance, reliability and usability," said Fernand Goldblat, Vice President and General Manager, BD Medical-Pharmaceutical Systems, Prefillable Syringes Platform. "We look forward to showcasing how BD partners with customers across the development lifecycle to help enable scalable, patient-centric solutions that support both clinical and operational objectives."

Where to Find BD
Booth: 4G28
BD will showcase a broad range of drug delivery technologies and lab testing services designed to address:

• High-viscosity formulations
• Large-volume subcutaneous delivery
• Single and dual-drug delivery for biologics and GLP-1s
• Increasing demand for connected and traceable manufacturing processes

BD also empowers pharmaceutical partners to differentiate their therapies by co-packing and co-delivering administration devices alongside the drug. With a broad portfolio of reconstitution, injection, and infusion devices, BD supports high-volume, high-viscosity formulations and complex dosing regimens, ensuring consistent performance and alignment with the drug's intended use.

As a Premium Partner of Pharmapack 2026, BD will also contribute to the conference program, sharing insights drawn from decades of experience in drug delivery and combination product development.

Keynote Sessions

• Wednesday, January 21 at 14:10
  Topic: "Are We There Yet? Dynamics in the High-Dose Biologics Market and the Emergence of the Large-Volume Subcutaneous Delivery Market."
• Wednesday, January 21 at 15:50
  Panel Discussion: "Patient-Centric Approaches to Complex Drug Delivery Challenges."

Learning Lab Sessions

• Wednesday, January 21 at 15:50
  Topic: "Unlocking High-Viscosity Biologic Delivery with BD Neopak™ XtraFlow™ Glass Prefillable Syringe and Comprehensive Injection Modeling."
• Thursday, January 22 at 10:50
  Topic: "Evaluating Plunger Movement and Container Closure Integrity of Combination Products Under Simulated Air Shipment Conditions."

Featured technologies

• BD Libertas™ Wearable Injector
  Ready-to-use, wearable injector for subcutaneous administration of high-dose biologics-enabling pharma to transition biologics from IV to SC delivery with potential for a positive patient experience.
• BD Neopak™ XtraFlow™ Glass Prefillable Syringe with BD SCF™ PremiumCoat® Plunger Stopper - Designed for subcutaneous delivery of high-viscosity biologics, this integrated system features a shorter 8mm needle and thinner wall technology for improved injection performance, paired with a plunger stopper engineered to reduce glide force and glide force variability.^1*
• BD iDFill™ Individual Prefillable Syringe Identification

Innovative RFID-based solution for prefillable syringes (PFS) aims to enhance efficiency and improve traceability during the fill & finish process and product distribution.

Live demonstrations available at the BD booth.

BD will also showcase newly announced products in development, featuring innovative solutions to address the growing demand for biologics. These include large-volume subcutaneous self-injection and dual-injection therapies, helping advance treatment flexibility and patient convenience. These advancements reinforce BD's commitment to driving innovation in drug delivery and improving health outcomes worldwide.

Additional Highlights
BD and ZebraSci - A BD Company - will present integrated combination product development services supporting customers from early concept through commercialization.
BD will also display elements of its broader drug delivery portfolio, including:

• BD Effivax™ Glass Prefillable Syringe for vaccines
• BD Hylok™ Glass Prefillable Syringe for acute drugs and hyaluronic acid
• BD Physioject™ Disposable Autoinjector and BD Vystra™ Disposable Pen for biologics, including GLP-1 therapies

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

About ZebraSci
ZebraSci is BD's independent combination testing and expert advisory platform. ZebraSci can partner with pharma and biotech companies on the development of their combination products with any type of injection device or delivery system.

ZebraSci delivers combination product expertise and testing services from concept to commercialization. Our broad suite of services ranges from device technology selection support, testing plans development for design verification and validation, testing execution as required by multiple approving bodies to post-launch supporting activities (complaint handling testing support, incoming inspection testing or final lot release programs)

For more information on ZebraSci, please visit zebrasci.com or connect with us on LinkedIn at https://www.linkedin.com/company/zebrasci-inc-/.

Contacts:
Media: Investors:
Fallon Mcloughlin Adam Reiffe
Director, Public Relations VP, Investor Relations
201.258.0361 201.847.6927
[email protected][email protected]

¹BD SCF™ PremiumCoat® Plunger Stopper 1-3mL Customer quality specifications. Le Pont-de-Claix, France; Becton, Dickinson and Company; 2023.

*When compared to the BD SCF™ FluroTec® Plunger Stopper. Results are based on a sample of 100 pieces of BD Flurotec® and BD SCF™ PremiumCoat®. Variables compared were Mean (glide force reduction) and standard deviation (glide force variability).

BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.

BD iDFill™ Individual Prefillable Syringe Identification is under development and is not a released product; statements contained herein are forward-looking and are subject to a variety of risks and uncertainties. Actual product may vary.

PremiumCoat is a registered trademark of AptarGroup, Inc.